Previous 10 | Next 10 |
NantKwest (NASDAQ: NK ) announces positive results from a Phase 1b clinical trial evaluating the combination of its antibody-targeted NK cells, ImmunityBio's N-803 (an IL-15 superagonist), low-dose chemo, adenoviral and yeast tumor-associated antigen vaccines (MUC1, brachyury, CEA) and a...
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care Disease cont...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a turbulent week, starting at 3,788.38 points on Monday’s (December 9) open and reaching a five day high of 3,808.32 points on Friday (December 13) as of 10:30 a.m. EST. However, as of 12:00 p.m. EST Friday, the index was sitting at ...
These Penny Stocks On Robinhood Rallied Last Week; Can That Continue Monday? This coming week has a lot going for it already and it isn’t even Monday yet. For those who like penny stocks , that could be a very good thing. Late last week we saw the US and China seemingly reach a Phase 1...
First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid tumors NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer ce...
NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that on Monday, December 2, 2019, it will ...
NantKwest (NASDAQ: NK ) perks up 17% after hours in response to final data from a Phase 2 clinical trial evaluating the combination of its off-the-shelf natural killer (aNK) cells and ImmunityBio's IL-15 superagonist N-803 in patients with a rare type of skin cancer called Me...
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the u...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) dipped steadily again last week, falling from 3,126.52 points on Monday’s (September 30) open to 3,1117.42 points as of 12:38 p.m. EDT on Friday (October 4). Last week started off with a bang when NewLink Genetics (NASDAQ: NLNK ) rev...
My plan for my investment in NantKwest ( NK ) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...